PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research
News Oct 27, 2005
Illumina, Inc. has announced an agreement of sale with PharmacoDesign (PD) for a BeadStation system and whole-genome genotyping arrays and reagents for ongoing pharmacogenomics studies.
PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation andpersonalizing treatment foroptimal clinical outcomes. Under the agreement, Illumina will gain access to biomarkers discovered by PD and will be able to incorporate such markers into proprietary SNP panels under a worldwide, royalty-bearing exclusive license.
PD will study diseases that include obesity, cancer and allergy-induced reactions such as atopy. The company works in partnership with large Korean hospitals to prescribe individualized treatments that utilize diet and "functional foods" in addition to traditionalpharmacological approaches. Initially, PD will utilize Illumina's Sentrix® Human-1 BeadChip, which contains over 100,000 SNP markers, 70% of which are located in or very near genes for direct disease association studies.
The Human-1 is powered by Illumina's Infinium™ assay, which allows investigators to query the entire genome with call rates, reproducibility and related performance metrics comparable to Illumina's GoldenGate® assay protocol, a gold standard of the HapMap Project. The Infinium assayenables virtually unconstrained, intelligent SNP selection for BeadChip array content.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.